CAMBRIDGE, Mass. and SINGAPORE--(BUSINESS WIRE)--Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, today announced the closing of a $14 million financing round backed by two new investors, Eli Lilly and Company and the strategic investment arm of the Singapore Economic Development Board, EDBI, as well as continued support from existing investors ClavystBio, Polaris Partners and S32..

马萨诸塞州剑桥市和新加坡——（商业新闻短讯）——Sunbird Bio是一家开发专有血液技术以改善神经系统疾病和早期癌症诊断和治疗的生物技术公司，今天宣布结束一轮1400万美元的融资，该融资由两名新投资者Eli Lilly and company和新加坡经济发展委员会战略投资部门EDBI支持，以及现有投资者ClavystBio、Polaris Partners和S32的持续支持。

The financing proceeds will enable Sunbird Bio to expand the clinical development of its proprietary blood-based diagnostic platform that has demonstrated potential to support earlier, more accurate diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease and other neurological disorders.

融资收益将使Sunbird Bio能够扩大其专有的基于血液的诊断平台的临床开发，该平台已证明有可能支持阿尔茨海默氏病，帕金森氏病和其他神经系统疾病的早期，更准确的诊断和治疗。

Sunbird Bio plans to open new, state-of-the-art laboratory space and initiate additional clinical studies of its diagnostic technology by early 2025..

Sunbird Bio计划在2025年初开放新的最先进的实验室空间，并启动其诊断技术的其他临床研究。

“This latest round of financing underscores our investors’ confidence in the potential of our diagnostic technology to transform outcomes for patients with neurological disorders,” said John McDonough, executive chair and CEO of Sunbird Bio. “This funding will enable us to accelerate the clinical development of our blood-based platform, which will offer physicians and patients multiple advantages as compared to currently available tests.

Sunbird Bio执行主席兼首席执行官约翰·麦克唐纳（JohnMcDonough）表示：“这一最新一轮融资突显了我们的投资者对我们的诊断技术改变神经系统疾病患者预后的潜力的信心。这笔资金将使我们能够加速我们基于血液的平台的临床开发，与目前可用的测试相比，该平台将为医生和患者提供多种优势。

With investment from two additional organizations that bring valuable strategic influence, we’re even better positioned to positively impact the millions of people globally who are affected by devastating neurological diseases.”.

随着另外两个组织的投资带来了宝贵的战略影响，我们甚至能够更好地为全球数百万受毁灭性神经疾病影响的人带来积极影响。”

Sunbird Bio’s blood-based diagnostic platform is the first technology that has demonstrated the ability to accurately and directly detect and monitor very low levels of disease-specific proteins, including amyloid beta (Aβ), tau and alpha synuclein (α-synuclein), that aggregate in the brain and play a key role in the pathogenesis of Alzheimer’s disease, Parkinson’s disease and other neurological disorders.

Sunbird Bio基于血液的诊断平台是第一个能够准确直接检测和监测极低水平疾病特异性蛋白质的技术，包括淀粉样蛋白β（Aβ），tau和α-突触核蛋白（α-突触核蛋白），这些蛋白质聚集在大脑中，并在阿尔茨海默氏病，帕金森氏病和其他神经系统疾病的发病机制中起关键作用。

Due to the proprietary design of the platform, Sunbird Bio has the unique capability to easily add assays to the platform as research continues to uncover new protein biomarkers that signal the presence of neurological diseases. This innovation creates the potential for Sunbird Bio to empower researchers and clinicians with the broadest panel of diagnostics that will deliver unparalleled insights not readily available from current tests..

由于平台的专有设计，Sunbird Bio具有独特的能力，可以轻松地将分析添加到平台中，因为研究不断发现新的蛋白质生物标志物，表明存在神经系统疾病。这项创新为Sunbird Bio创造了潜力，使研究人员和临床医生能够获得最广泛的诊断方法，从而提供当前测试无法提供的无与伦比的见解。

“EDBI is excited to partner with Sunbird Bio as part of Singapore’s vibrant and growing community of life science companies developing groundbreaking solutions to address unmet global clinical needs,” said Christine Giam, partner at EDBI. “The nation’s robust research ecosystem, coupled with its pro-business environment and strong intellectual property protection, offers a fertile ground for innovators to advance their discoveries, and we look forward to partnering with more companies to grow and expand their footprint in Singapore.”.

EDBI合伙人克里斯蒂娜·贾姆（ChristineGiam）表示：“EDBI很高兴与Sunbird Bio合作，作为新加坡充满活力和不断发展的生命科学公司社区的一部分，开发突破性的解决方案，以满足未满足的全球临床需求。国家强大的研究生态系统，加上其有利的商业环境和强大的知识产权保护，为创新者推进其发现提供了沃土，我们期待与更多公司合作，以扩大其在新加坡的足迹。”

Sunbird Bio, which is jointly headquartered in Cambridge, Massachusetts and Singapore, is actively securing partnerships with biopharma companies and others to accelerate the development of its diagnostic platform and conduct clinical studies. Use cases include patient enrollment, longitudinal monitoring, patient stratification and target engagement..

Sunbird Bio联合总部位于马萨诸塞州剑桥市和新加坡，正在积极与生物制药公司和其他公司建立合作伙伴关系，以加速其诊断平台的开发并进行临床研究。用例包括患者登记、纵向监测、患者分层和目标参与。

“Sunbird Bio is on the forefront of innovation in diagnostics for neurological diseases, as evidenced by the promising clinical data generated to date from its diagnostic platform,” said Alexandra Cantley, Ph.D., partner at Polaris Partners. “Our continued investment in the company illustrates our confidence that Sunbird will drive meaningful change for patients, particularly in an area where, until lately, there has been little progress.

Polaris Partners的合伙人Alexandra Cantley博士说：“太阳鸟生物（Sunbird Bio）处于神经系统疾病诊断创新的前沿，其诊断平台迄今产生的有前途的临床数据证明了这一点。”。“我们对该公司的持续投资表明，我们相信Sunbird将为患者带来有意义的改变，特别是在直到最近进展甚微的领域。

We believe Sunbird Bio’s vision, talented team of experts and novel diagnostic technology could significantly impact diagnosis and treatment of neurological disorders in the near term.”.

我们相信，Sunbird Bio的远见、才华横溢的专家团队和新颖的诊断技术可以在短期内对神经系统疾病的诊断和治疗产生重大影响。”

About Sunbird Bio

关于太阳鸟生物

Sunbird Bio is a biotechnology company developing proprietary blood-based diagnostic tests that provide unprecedented insights to enable earlier, more accurate diagnosis and treatment of neurological disorders and early-stage cancer. Sunbird’s innovative technologies uniquely detect the property and activity of proteins to empower researchers and clinicians with actionable information that is not available or accessible from current tests.

Sunbird Bio是一家生物技术公司，开发专有的基于血液的诊断测试，提供前所未有的见解，以实现对神经系统疾病和早期癌症的早期，更准确的诊断和治疗。Sunbird的创新技术独特地检测蛋白质的性质和活性，为研究人员和临床医生提供当前测试无法获得或无法获得的可行信息。

Sunbird Bio’s unparalleled leadership in blood-based diagnostics positions the company to become a global leader in the field, addressing significant research and clinical gaps, and serving multiple, sizable markets..

Sunbird Bio在血液诊断领域无与伦比的领导地位使该公司成为该领域的全球领导者，解决了重大的研究和临床差距，并服务于多个规模较大的市场。